Skip to content

Study · Not a test of the peptide alone · 1998

6 results

Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.

Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G

European journal of pediatrics1 May 1998Cited by 61 (Europe PMC)

PMID9625331 (opens in a new tab)DOI10.1007/s004310050831 (opens in a new tab)PepBankPUB-09625331
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In girls with progressive precocious puberty, BMD after pooled GnRH analogue treatment did not differ significantly from controls.

    In plain wordsIn girls receiving mixed GnRH analogues, bone density did not differ significantly from controls.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBMD versus controls
    Study

    n = 34

    Comparator
    Control group
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Lumbar BMD
    1.11 g/cm2
    group 1, pooled GnRH analogue treatment
    Lumbar BMD
    1.18 g/cm2
    control group (n=20)

    Source sentences

    Summary
    BMD values (group 1: 1.11+/-0.14 g/cm2, group 2: 1.22+/-0.08 g/cm2) were not significantly different from those of a control group (1.18+/-0.10 g/cm; n=20, age 16.3-20.5 years) and the patients' mothers (group 1: 1.16+/-0.07 g/cm2, n=11, age 32.9-45.1 years; group 2: 1.20+/-0.08 g/cm2, n=7, age 33.5-46.5 years).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In girls with progressive precocious puberty, BMD after pooled GnRH analogue treatment did not differ significantly from their mothers.

    In plain wordsIn girls receiving mixed GnRH analogues, bone density did not differ significantly from their mothers.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBMD versus mothers
    Study

    n = 25

    Comparator
    Patients' mothers
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Lumbar BMD
    1.11 g/cm2
    group 1, pooled GnRH analogue treatment
    Lumbar BMD
    1.16 g/cm2
    group 1 mothers (n=11)

    Source sentences

    Summary
    BMD values (group 1: 1.11+/-0.14 g/cm2, group 2: 1.22+/-0.08 g/cm2) were not significantly different from those of a control group (1.18+/-0.10 g/cm; n=20, age 16.3-20.5 years) and the patients' mothers (group 1: 1.16+/-0.07 g/cm2, n=11, age 32.9-45.1 years; group 2: 1.20+/-0.08 g/cm2, n=7, age 33.5-46.5 years).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In girls with progressive precocious puberty, pooled GnRH analogue treatment produced final height above pretreatment predictions.

    In plain wordsIn girls with precocious puberty, final height after mixed GnRH analogue treatment exceeded pretreatment predictions.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFinal height versus predicted height
    Study

    n = 14

    Comparator
    Pretreatment predicted height
    Outcome group
    Linear growth · Musculoskeletal

    Measurements

    Final height
    158.9 cm
    group 1, pooled GnRH analogue treatment
    Pre-treatment predicted height
    153.5 cm
    group 1

    Source sentences

    Summary
    In group 1, final height (158.9+/-5.4 cm) was significantly greater than the pre-treatment predicted height (153.5+/-7.2 cm, P < 0.001), but significantly lower than mid-parental height (163.2+/-6.2 cm, P < 0.005).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In girls with progressive precocious puberty, final height after pooled GnRH analogue treatment remained below mid-parental height.

    In plain wordsIn girls with precocious puberty, final height after mixed GnRH analogue treatment remained below parental height predictions.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFinal height versus mid-parental height
    Study

    n = 14

    Comparator
    Mid-parental height
    Outcome group
    Linear growth · Musculoskeletal

    Measurements

    Final height
    158.9 cm
    group 1, pooled GnRH analogue treatment
    Mid-parental height
    163.2 cm
    group 1

    Source sentences

    Summary
    In group 1, final height (158.9+/-5.4 cm) was significantly greater than the pre-treatment predicted height (153.5+/-7.2 cm, P < 0.001), but significantly lower than mid-parental height (163.2+/-6.2 cm, P < 0.005).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In GnRH analogue-treated girls, final height was higher after stopping at the younger bone age than the older bone age.

    In plain wordsIn girls receiving mixed GnRH analogues, final height was higher when treatment stopped at a younger versus older bone age.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFinal height by stopping bone age
    Study

    n = 14

    Comparator
    Stopping at bone age >=12.0 years
    Outcome group
    Linear growth · Musculoskeletal

    Measurements

    Final height
    163.7 cm
    stopped therapy at bone age <=11.5 years (n=5)
    Final height
    156.5 cm
    stopped therapy at bone age >=12.0 years (n=9)

    Source sentences

    Summary
    Subdividing the girls of group 1 according to the bone age at discontinuation of therapy (i.e. or =12.0 years, n=9), the former patients had a final height significantly higher than the latter (163.7+/-3.9 cm vs 156.5+/-4.6 cm, P < 0.02).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In GnRH analogue-treated girls, BMD was higher after stopping at the younger bone age than the older bone age.

    In plain wordsIn girls receiving mixed GnRH analogues, bone density was higher when treatment stopped at a younger versus older bone age.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseBMD by stopping bone age
    Study

    n = 14

    Comparator
    Stopping at bone age >=12.0 years
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Lumbar BMD
    1.22 g/cm2
    stopped therapy at bone age <=11.5 years
    Lumbar BMD
    1.04 g/cm2
    stopped therapy at bone age >=12.0 years

    Source sentences

    Summary
    In group 1, the girls who stopped therapy at a bone age or =12.0 years (1.04+/-0.12 g/ cm2, P < 0.05).
    1 context sentence
    Summary · context
    Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 microg/daily), subsequently switched to depot triptorelin (60 microg/kg/26-28 days);

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.